MedTrace Logo

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

NCT05366478 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-08-02

No results posted yet for this study

Summary

This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.

Conditions

  • Melanoma
  • Non Small Cell Lung Cancer
  • Cervical Carcinoma

Interventions

DRUG

Autologous tumor infiltrating lymphocytes (TILs)

A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.

Sponsors & Collaborators

  • Suzhou BlueHorse Therapeutics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Fenge Le, Ph.D · Tianjin Beichen Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-30
Primary Completion
2024-05-30
Completion
2029-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05366478 on ClinicalTrials.gov